Posted by Michael Wonder on 15 Jan 2025
Capivasertib in combination with fulvestrant for the treatment of patients with advanced, hormone receptor positive, HER2 negative breast cancer after endocrine treatment
14 January 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use of capivasertib in the NHS in England.
For the time being, capivasertib, when used in combination with fulvestrant, is not recommended for the treatment of adults with locally advanced or metastatic, hormone receptor positive, HER2 negative (defined as immunohistochemistry [IHC]0 or IHC1 positive, or IHC2 positive or in situ hybridisation [ISH]1 negative) breast cancer that has one or more PIK3CA, AKT1 or PTEN gene alterations and has recurred after or progressed on endocrine treatment.
